The Case for Generic and Follow-On Biologics

Overview:

Since the 1980s, biotechnology has revolutionized the practice of medicine and the pharmaceutical industry. The biotechnology revolution has not come cheap, however. Many biopharmaceuticals cost thousands of dollars for a course of treatment that can last months or years. Due to the industry’s relative youth, most of these medicines are still protected by patents. But, because many of the patents are slated to expire in the next decade, there is a growing interest among patients, insurers, governments, and the generic drug industry in the production of generic biopharmaceuticals.

Click below to access this 42-page, 180KB white paper.  

Author: Gregory Conko  | File Type: pdf

Find more white papers on Industry Developments

View all white papers»